Topiramate plus Cooling for Hypoxic-Ischemic Encephalopathy: A Randomized, Controlled, Multicenter, Double-Blinded...

Area of Science:

• Neonatal neurology
• Neurocritical care
• Pharmacology

Background:

• Hypoxic-ischemic encephalopathy (HIE) is a major cause of neonatal brain damage.
• Whole-body cooling is a standard HIE treatment, but therapeutic interventions to improve efficacy are needed.
• Topiramate has shown neuroprotective effects in experimental models of brain injury.

Purpose of the Study:

• To evaluate topiramate's efficacy in reducing antiepileptic activity in neonates with HIE undergoing therapeutic hypothermia.
• To assess whether topiramate reduces brain damage as a consequence of seizure reduction.

Main Methods:

• A randomized, double-blind, placebo-controlled multicenter trial involving 110 neonates with HIE.
• Topiramate or placebo administered at hypothermia initiation, with continuous EEG monitoring.
• Pharmacokinetic analysis, biochemical markers of brain injury, and MRI assessments were performed.

Main Results:

• The topiramate group showed a trend towards reduced seizure burden (25.9% vs. 42%) and lower mortality (9.2% vs. 19.2%), though not statistically significant.
• Therapeutic topiramate levels were achieved in 37.5% at 24h and 75.5% at 48h.
• A significant association was found between serum topiramate levels and seizure activity (p < 0.016).

Conclusions:

• Topiramate demonstrated a trend in reducing seizures and mortality in HIE neonates, particularly in those achieving therapeutic levels.
• Current dosing strategies may be insufficient; further research with optimized topiramate dosing is warranted.
• Topiramate's potential as an adjunctive therapy for HIE requires further investigation.